Nowadays, crizotinib is used in various molecular mutations such as ROS‐1 and C‐MET as well as ALK‐positive NSCLC, so this study will help clinicians understand efficacy and AEs. The gene discussed is ALK; the disease is non-small cell lung carcinoma.